Table 5.
Genotype distribution and prostate cancer risk for the RAD51, RAD51B, XRCC2, and XRCC3 polymorphisms in prostate cancer patients and control group.
| Genotype/allele | Prostate cancer patients (n = 101) |
Control group (n = 216) |
OR [95% Cl] | P value |
|---|---|---|---|---|
| rs1801320 | ||||
| GG | 66 (65.3) | 172 (79.5) | 1 [Ref.] | |
| GC | 27 (26.7) | 37 (17.3) | 1.90 [1.07–3.37] | 0.03 |
| CC | 8 (8.0) | 7 (3.2) | 2.98 [1.04–8.54] | 0.04 |
| G | 159 (78.7) | 381 (88.2) | 1 [Ref.] | |
| C | 43 (21.3) | 51 (11.8) | 2.02 [1.29–3.16] | <0.01 |
|
| ||||
| rs1801321 | ||||
| GG | 39 (38.6) | 67 (31.0) | 1 [Ref.] | |
| TG | 4 (4.0) | 8 (3.7) | 0.86 [0.24–3.04] | 1 |
| TT | 58 (57.4) | 141 (65.3) | 0.71 [0.43–1.16] | 0.17 |
| G | 82 (40.6) | 142 (32.9) | 1 [Ref.] | |
| T | 120 (59.4) | 290 (67.1) | 0.72 [0.51–1.01] | 0.06 |
|
| ||||
| rs10483813 | ||||
| TT | 56 (55.4) | 134 (62.0) | 1 [Ref.] | |
| TA | 40 (39.6) | 68 (31.5) | 1.41 [0.85–2.32] | 0.18 |
| AA | 5 (5.0) | 14 (6.5) | 0.85 [0.29–2.49] | 0.78 |
| T | 152 (75.2) | 336 (77.8) | 1 [Ref.] | |
| A | 50 (24.8) | 96 (22.2) | 1.15 [0.78–1.70] | 0.48 |
|
| ||||
| rs3784099 | ||||
| GG | 49 (48.5) | 122 (56.5) | 1 [Ref.] | |
| GA | 41 (40.6) | 80 (37.0) | 1.28 [0.77–2.11] | 0.34 |
| AA | 11 (10.9) | 14 (6.5) | 1.96 [0.83–4.61] | 0.12 |
| G | 139 (68.8) | 324 (75.0) | 1 [Ref.] | |
| A | 63 (31.2) | 108 (25.0) | 1.36 [0.94–1.97] | 0.10 |
|
| ||||
| rs3218536 | ||||
| GG | 90 (89) | 196 (90.7) | 1 [Ref.] | |
| GA | 11 (11.0) | 20 (9.3) | 1.20 [0.55–2.60] | 0.65 |
| AA | 0 (0.0) | 0 (0.0) | — | |
| G | 191 (94.6) | 412 (95.4) | 1 [Ref.] | |
| A | 11 (5.4) | 20 (4.6) | 1.19 [0.56–2.53] | 0.65 |
|
| ||||
| rs861539 | ||||
| CC | 54 (53.5) | 119 (55.1) | 1 [Ref.] | |
| CT | 34 (33.7) | 75 (34.7) | 1.00 [0.60–1.68] | 1.00 |
| TT | 13 (12.8) | 22 (10.2) | 1.30 [0.61–2.78] | 0.49 |
| C | 142 (70.3) | 313 (72.5) | 1 [Ref.] | |
| T | 60 (29.7) | 119 (27.5) | 1.11 [0.77–1.61] | 0.57 |